About US
Contact us
-
Breakthrough hep C meds aren't yet for sale, but critics already taking aim at pricesThe next generation ofhepatitis Ctreatments has investors excited--not to mention doctors, patients and drug company executives. But if the past is any indicator, those newfangled drugs are likely to2013/11/13
-
Bridging the Gap Between Basic Research and Industrial ApplicationProfessor Dr Pierre Jacobs, KU Leuven (Belgium), has received the BASF-DECHEMA Alwin Mittasch Special Prize for his research into materials and their use as process catalysts. The award, which comes w2013/11/13
-
Capsugel's Vcaps Plus HPMC Capsules Enhance Performance for Recently Approved LevomilnacipranCapsugel'sVcaps Plus HPMC (hypromellose) capsules are increasingly the preferred capsule option among pharmaceutical companies looking for innovative dosage forms to enhance product performance and im2013/11/12
-
Merck’s Investigational Grass Sublingual Allergy Immunotherapy Tablet Significantly Reduced Allergy Symptoms in Pivotal Phase III StudyMerck, known as MSD outside the US and Canada,has announced data for its investigational Timothy grass sublingual allergy immunotherapy tablet (MK-7243) from a study involving 1501 North American adul2013/11/12
-
Advaxis's cancer vaccine gets FDA orphan status for treatment of HPV-associated head and neck cancerUS-based clinical-stage biotechnology firm Advaxis has received orphan drug designation from the US Food and Drug Administration (FDA) for its lead drug candidate ADXS-HPV to treat human papillomaviru2013/11/11
-
Alzheimer'​s Disease Market to Witness Slight Increase by 2019As a result of Phase III therapy LMTX potentially entering the Alzheimer’s Disease (AD) industry in the near future, the AD market will increase slightly from $3.6 billion in 2012 to $3.8 billion in 22013/11/11
-
Gastro specialist Salix nabs Santarus and new colitis drug in $2.6B dealSalix Pharmaceuticals, the gastrointestinal drug specialist, has snapped up fellow specialty drugmaker Santarus in a $2.6 billion all-cash buyout. The deal will add a clutch of Santarus products to S2013/11/8
-
Bayer envisions bigger Eylea market with new EU useBayerhas taken another step toward fulfilling blockbuster ambitions for its eye drugEylea. The German drugmaker asked European regulators to approve the vision-loss treatment for patients with diabeti2013/11/8
-
Januvia's Q3 Performanc​e Proves Importance of Business Strategy for Type 2 Diabetes DrugsFollowing what was once the rising success of Merck’s first-to-market DPP-4 inhibitor, Januvia, which achieved significant sales of $4 billion in 2012, the unexpectedly poor performance of the type 22013/11/7
-
Novartis plots sales cuts in U.K. amid R&D restructuringNovartis ($NVS) has brought its job-cutting sword to the U.K., with plans to shutter an R&D site in Horsham. Up to 371 jobs are expected to disappear there. But that's not all. The Swiss drugmaker2013/11/7